Get personalized, coordinated care across Northern California through the Sutter network.
View Patient Resources
Make appointments, message your doctor and more through our patient portal.
Enroll NowOur contributions to medical research and education lead to better healthcare outcomes.
Research at Sutter
Join our robust training programs led by nationally known healthcare leaders.
Explore OpportunitiesExplore the ways we provide innovative, compassionate care through our network.
Learn About Sutter Health
Shape the future of healthcare and build your career within our diverse teams.
Find Jobs14results found for:
T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial
Status: Active, Not Recruiting
Evaluating the Addition of Adj Chemo to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients
Status: Active, Recruiting
A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive
Status: Active, Not Recruiting
The purpose of this study is to find out how genetics, biologics and behavior might contribute to
Status: Active, Recruiting
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
Status: Active, Recruiting
Testing Radiation and HER2-targeted Therapy Versus HER2-targeted Therapy Alone for Low-risk HER2-positive Breast Cancer
Status: Active, Recruiting
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
Status: Active, Recruiting
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer
Status: Active, Recruiting
A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With The Physician's Choice o
Status: Active, Recruiting
A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With The Physician's Choice of Endocrine Therapy Plus Everolimus in Particip
Status: Active, Recruiting
